Filtered By:
Specialty: Drugs & Pharmacology
Cancer: Breast Cancer
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 139 results found since Jan 2013.
Glucose-regulated protein of 94 kDa contributes to the development of an aggressive phenotype in breast cancer cells
Publication date: September 2018 Source:Biomedicine & Pharmacotherapy, Volume 105 Author(s): Pedro Buc Calderon, Anne-Laure Sennesael, Christophe Glorieux Grp94 plays an essential role in protein assembly. We previously suggested that Grp94 overexpression is involved in tumor aggressiveness. However, the underlying mechanisms remain unknown. Since many tumors display high Grp94 levels, we investigated the effects of tumor microenvironment on the regulation of this chaperone expression. First, we found out that hypoxia did not change Grp94 expression in the human tumor cell lines MCF-7 (breast cancer) and HepG2 (li...
Source: Biomedicine and Pharmacotherapy - May 29, 2018 Category: Drugs & Pharmacology Source Type: research
Down-regulation of KIF2A inhibits gastric cancer cell invasion via suppressing MT1-MMP.
In conclusion, our study reveals that down-regulation of KIF2A can inhibit gastric cancer cell invasion by suppressing MT1-MMP. This article is protected by copyright. All rights reserved.
PMID: 29781531 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Pharmacology and Physiology - May 21, 2018 Category: Drugs & Pharmacology Authors: Zhao P, Lan F, Zhang H, Zeng G, Liu D Tags: Clin Exp Pharmacol Physiol Source Type: research
AKT2 siRNA delivery with amphiphilic-based polymeric micelles show efficacy against cancer stem cells.
Authors: Rafael D, Gener P, Andrade F, Seras-Franzoso J, Montero S, Fernández Y, Hidalgo M, Arango D, Sayós J, Florindo HF, Abasolo I, Schwartz S, Videira M
Abstract
Development of RNA interference-based therapies with appropriate therapeutic window remains a challenge for advanced cancers. Because cancer stem cells (CSC) are responsible of sustaining the metastatic spread of the disease to distal organs and the progressive gain of resistance of advanced cancers, new anticancer therapies should be validated specifically for this subpopulation of cells. A new amphihilic-based gene delivery system that combines Plu...
Source: Drug Delivery - April 20, 2018 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
Characterization of modified mesoporous silica nanoparticles as vectors for siRNA delivery
Publication date: Available online 21 February 2018 Source:Asian Journal of Pharmaceutical Sciences Author(s): Anna Slita, Anna Egorova, Eudald Casals, Anton Kiselev, Jessica M. Rosenholm Gene therapy using siRNA molecules is nowadays considered as a promising approach. For successful therapy, development of a stable and reliable vector for siRNA is crucial. Non-viral and non-organic vectors like mesoporous silica nanoparticles (MSN) are associated with lack of most viral vector drawbacks, such as toxicity, immunogenicity, but also generally a low nucleic acid carrying capacity. To overcome this hurdle, we here modified t...
Source: Asian Journal of Pharmaceutical Sciences - April 14, 2018 Category: Drugs & Pharmacology Source Type: research
Long non-coding RNA BANCR indicates poor prognosis for breast cancer and promotes cell proliferation and invasion.
CONCLUSIONS: LncRNA BANCR is highly expressed in breast cancer, which is significantly correlated with the prognosis of patients; moreover, it can promote the growth, invasion and metastasis of ovarian cancer cells. The down-regulation of BANCR can inhibit the proliferation, invasion and metastasis capacities of MCF-7 cells.
PMID: 29565494 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - March 24, 2018 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Systemic Administration of siRNA with Anti-HB-EGF
Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative
Breast Cancer
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.7b01055
Source: Molecular Pharmaceutics - March 12, 2018 Category: Drugs & Pharmacology Authors: Ayaka Okamoto, Tomohiro Asai, Yusuke Hirai, Kosuke Shimizu, Hiroyuki Koide, Tetsuo Minamino and Naoto Oku Source Type: research
ASAP Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.7b01055
Source: Molecular Pharmaceutics - March 12, 2018 Category: Drugs & Pharmacology Authors: Ayaka Okamoto, Tomohiro Asai, Yusuke Hirai, Kosuke Shimizu, Hiroyuki Koide, Tetsuo Minamino, Naoto Oku Source Type: research
The LPI/GPR55 axis enhances human breast cancer cell migration via HBXIP and p-MLC signaling.
In this study we first showed that GPR55 expression levels in 38 metastatic lymph nodes of breast cancer patients were profoundly elevated, and were positively associated in human breast cancer cells with their migratory ability. Moreover, the plasma levels of GPR55 endogenous agonist L-a-lysophosphatidylinositol (LPI) were significantly increased in breast cancer patients compared with healthy individuals. In human breast cancer LM-MCF-7 and MDA-MB-231 cells, treatment with LPI (2.5 μmol/L) significantly increased filopodia formation and resulted in cell migration, which could be blocked either by the GPR55 antagonist CI...
Source: Acta Pharmacologica Sinica - November 30, 2017 Category: Drugs & Pharmacology Authors: Zhou XL, Guo X, Song YP, Zhu CY, Zou W Tags: Acta Pharmacol Sin Source Type: research
Carbonate apatite nanoparticles carry siRNA(s) targeting growth factor receptor genes egfr1 and erbb2 to regress mouse breast tumor.
Authors: Tiash S, Kamaruzman NIB, Chowdhury EH
Abstract
Cancer cells lose their control on cell cycle by numerous genetic and epigenetic alterations. In a tumor, these cells highly express growth factor receptors (GFRs), eliciting growth, and cell division. Among the GFRs, epidermal growth factor receptor-1 (EGFR1) (Her1/ERBB1) and epidermal growth factor receptor-2 (EGFR2) (Her2/ERBB2) from epidermal growth factor (EGF) family and insulin-like growth factor-1 receptor (IGF1R) are highly expressed on breast cancer cells, thus contributing to the aggressive growth and invasiveness, have been focused in this study. M...
Source: Drug Delivery - November 10, 2017 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance
Publication date: 20 December 2017 Source:International Journal of Pharmaceutics, Volume 534, Issues 1–2 Author(s): Tingting Meng, Binbin Lu, Shihong Shao, Ming Yuan, Xuan Liu, Hong Yuan, Xuan Huang, Fuqiang Hu P-glycoprotein (P-gp) is a major efflux transporter overexpressed on multidrug resistant tumor cells and responsible for pumping drugs out. If anti-tumor drugs are given when P-gp level is low, satisfactory treatment efficiency may be achieved. Thus, a P-gp down-regulating siRNA (siMDR1) and doxorubicin (DOX) were applied to eliminate multidrug resistant breast cancer cells (MCF-7/ADR). A redox-responsive glucoli...
Source: International Journal of Pharmaceutics - November 6, 2017 Category: Drugs & Pharmacology Source Type: research
Stealth magnetic nanocarriers of siRNA as platform for breast cancer theranostics
Publication date: 5 November 2017 Source:International Journal of Pharmaceutics, Volume 532, Issue 2 Author(s): J. Bruniaux, S. Ben Djemaa, K. Hervé-Aubert, H. Marchais, I. Chourpa, S. David The endogenous mechanism of RNA interference is more and more used in research to obtain specific down-regulation of gene expression in diseases such as breast cancer. Currently, despite the new fields of study open up by RNA interference, the rapid degradation of siRNA by nucleases and their negative charges prevent them from crossing cell membranes. To overcome these limitations, superparamagnetic iron oxide nanoparticles (SPIONs) ...
Source: International Journal of Pharmaceutics - October 11, 2017 Category: Drugs & Pharmacology Source Type: research
Functional impact of Galectin-3 and TRAIL expression in breast cancer cells.
CONCLUSIONS: The expression level of Galectin-3 in breast cancer tissues was significantly increased compared with that in normal tissues, while the level of TRAIL protein was significantly decreased in cancer tissue. The biological role of these two proteins seems to be synergistic in inhibiting apoptosis of cancer cells. Therefore, the evaluation method that combined both Galectin-3 and TRAIL is of great clinical value in the evaluation of clinical prognosis of patients with breast cancer.
PMID: 28925481 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - September 21, 2017 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Identification of 2,4-dihydroxy-5-pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein-1 (YB-1) and its therapeutic actions against breast cancer.
In this study, we determined that DPI was toxic to breast cancer cell lines as individual drug as well as in combination with DOX. Moreover, immunofluorescence and confocal studies showed that DPI decreases DOX induced YB-1 nuclear translocation and increases DOX accumulation in breast cancer cell line. A G1/G0 phase cell cycle arrest and apoptosis was also induced by DPI. Moreover, DPI modulated YB-1 downstream targets such as p53, caspase-3, CDK-1 which are involved in cell cycle progression and apoptosis. Further, metastatic functional analysis revealed that DPI inhibits cell adhesion, migration, invasion in aggressive ...
Source: European Journal of Pharmaceutical Sciences - September 12, 2017 Category: Drugs & Pharmacology Authors: Gunasekaran VP, Nishi K, Sivakumar D, Sivaraman T, Mathan G Tags: Eur J Pharm Sci Source Type: research
In vitro studies of phospholipid-modified PAMAM-siMDR1 complexes for the reversal of multidrug resistance in human breast cancer cells
In this study, we designed a new carrier system loaded with a functional siRNA targeting MDR1 gene to reverse multi-drug resistance (MDR) in human breast cancer MCF-7/ADR cells. Phospholipid-modified PAMAM-siMDR1 complexes were designed on the external decoration of polyamidoamine (PAMAM) with phospholipid (PL) and the electrostatical interaction between PAMAM and siMDR1 to form hybrid nanocomplexes (PL-dendriplexes). Compared with siMDR1 and dendriplexes (PAMAM-siMDR1), this delivery system represented higher gene silencing efficiency, enhanced cellular uptake of siMDR1, decreased p-gp expression, raised cellular accumula...
Source: International Journal of Pharmaceutics - August 5, 2017 Category: Drugs & Pharmacology Source Type: research
Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis
Publication date: 30 August 2017 Source:International Journal of Pharmaceutics, Volume 529, Issues 1–2 Author(s): Xinyan Chen, Yidi Zhang, Chunming Tang, Chunli Tian, Qiong Sun, Zhigui Su, Lingjing Xue, Yifan Yin, Caoyun Ju, Can Zhang The overexpression of survivin in breast cancer cells is an important factor of paclitaxel (PTX) resistance in breast cancer. To overcome PTX resistance and improve the antitumor effect of PTX, we developed a novel liposome-based nanosystem (PTX/siRNA/SS-L), composed of a redox-sensitive cationic oligopeptide lipid (LHSSG2C14) with a proton sponge effect, natural soybean phosphatidylcholin...
Source: International Journal of Pharmaceutics - June 29, 2017 Category: Drugs & Pharmacology Source Type: research
